Description
Imaging plays an important role in oncology from early development to surrogate endpoints in pivotal trials. PET scanning allows for assessing biodistribution in early phases, while phase III trials typically require anatomical imaging using the RECIST criteria. This session focuses on the practical issues relating to standardization and compliance issues for imaging endpoints in early and late phase oncology clinical trials.
Within thewebinar the application of imaging as a biomarker will be explored including the complexities of their pitfalls and newer approaches to overcoming them.
Approaches to standardization and combinations of imaging tools to provide a complete picture are increasingly employed to overcome traditional shortfalls.
A critical part of imaging in clinical trials is around the logistical issues. This session highlights best practices from an experienced investigator who summarizes the challenges and current solutions.
Learning Objectives
At the end of the webinar, learners will:
• Gain an insight into the current issues relating to the application of imaging as a biomarker
• List standardization challenges
• List compliance issues in imaging studies
• Review imaging tools used in clinical research, including their strengths and limitations
• Gain an insight into the practical considerations and regulatory issues involved in imaging in oncology clinical research
• Outline current best practice principles in the area.
The Expert
Bruno Morgan trained in medicine at Christ Church, Oxford University and the University of Oxford Medical School. He is Professor of Cancer Imaging and Radiology at the Department of Cancer Studies and Molecular Medicine at the University of Leicester. His research interests include cross sectional imaging (U/S, CT and MRI) focusing on oncology, as imaging as a biomarker for the treatment of cancer, as well as forensic imaging.
